Shingles Vaccine Likely to Be Cost-EffectiveShingles Vaccine Likely to Be Cost-Effective
Vaccinating older adults against herpes zoster (HZ) and postherpetic neuralgia (PHN) is probably cost-effective, according to a critical review of the literature. Reuters Health Information
AbstractHerpes zoster (shingles) is the reactivation of dormant varicella zoster virus in individuals who previously experienced varicella infection or vaccination. Herpes zoster can occur in pregnancy, although it is rare. This case report describes the clinical presentation and diagnosis of herpes zoster and reviews current recommendations for treatment. Preventative measures and the role of immunization are discussed in addition to clinical implications for intrapartum, postpartum, and newborn care to guide practitioners in caring for women experiencing or exposed to herpes zoster in pregnancy.
The higher risk for stroke with herpes zoster was not attenuated by antivirals or Zostavax vaccination in older patients, but that shouldn't slow vaccination rates or further study.Medscape Medical News
Shingles is becoming less common in both adults and children in the U.S., according to results from a database study.Reuters Health Information
(MedPage Today) -- Vaccine development may help with prevention of herpes zoster in this population
This report evaluates the fifth year of the shingles vaccination programme in England from 2017 to 2018.
hon Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate either spontaneously or after a number of triggering factors to cause herpes zoster (shingles). Varicella and its complications are more severe in the immunosuppressed. The most frequent and important complication of VZV reactivation is postherpetic neuralgia, the cause of which is unknown and for which treatment is usually ineffective. Reactivation of VZV may also cause a wide variety of neurologic...
AbstractThe herpes zoster (shingles) vaccine is recommended for all adults aged ≥ 60 years without contraindications to prevent shingles and post-herpetic neuralgia. There are no published studies on zoster vaccination rates, barriers, or workflows in adults who have experienced homelessness. Due to barriers specific to this vaccine, including difficulty determining insura nce coverage, high upfront costs, need for storage in a freezer, and under-prescription by physicians, uptake is lower compared to other recommended vaccines for older adults. To address these barriers, we developed a new approach of partn...
This article discusses new vaccination recommendations for herpes zoster.
Abstract As primary care providers and experts on diseases affecting the skin, such as herpes zoster (shingles) and human papillomavirus-related cancers, dermatologists are often asked to make important recommendations on vaccines and vaccinations; however, a rise in antivaccine attitudes-sometimes referred to as "vaccine hesitancy"-among patient populations, especially in North America and Europe, has created new challenges for the practicing dermatologist. Here we provide a brief overview of some of the major evidence that refutes commonly held misperceptions about vaccines. PMID: 30207522 [PubMed - in process]
CONCLUSIONS: ZVL reduced the risk of shingles among an elderly population. Given the negative impact of shingles and PHN on QoL, the benefits of vaccination are clear. Improving uptake in the UK is needed in this population. PMID: 30195489 [PubMed - as supplied by publisher]